OpenNashEarnings

Aflac (AFL) · Insurance

Aflac Q2 2026 earnings: summary, key numbers & outlook

Results filed 6 Aug 2026 · Quarter ended 30 Jun 2026

Press release ↗Investor relations ↗

Summaries and transcripts are machine-generated and can contain errors.

In brief

Aflac Japan's new Anshin Palette medical and refreshed Tsumitasu life products drove growth, offsetting a high Miraito cancer comparison, while U.S. sales gained from group voluntary benefits and network dental and vision.

Aflac's product launches in Japan are the main business story. Anshin Palette, a new medical insurance product launched in December 2025, and the refreshed Tsumitasu savings-type life insurance grew strongly. Japan sales fell 5.6% for the quarter only because Miraito cancer insurance, launched in March 2025, set a high bar. In the U.S., sales rose 2.6%, helped by group voluntary benefits and network dental and vision products.

Management is steering toward more profitable growth, more reinsurance in Japan, and a push to get brokers to adopt network dental in the second half. Aflac Japan's reinsurance target is now up to 30% of FSA reserves, aiming for a higher return on equity. The tension is that new products are bringing somewhat elevated lapse and reissue activity in Japan, while U.S. premium growth for 2026 is now expected just below its guided range.

No call transcript for this quarter, so this summary also draws on: The Motley Fool ↗.

Key numbers

Total revenues · GAAP
$4.1 billion

down 1.0% from a year ago

Net earnings · GAAP
$825 million

up from $599 million a year ago

Net earnings per diluted share · GAAP
$1.63

up from $1.11 a year ago

Adjusted earnings per diluted share · non-GAAP
$1.75

down 1.7% from a year ago

Adjusted earnings · non-GAAP
$883 million

down 7.7% from a year ago

Segment or metricValueChange
Aflac Japan new annualized premium sales¥19.6 billiondown 5.6%
Aflac U.S. sales$349 millionup 2.6%
Aflac Japan premium persistency92.7%down 100 bps
Aflac U.S. persistency79.4%up 20 bps
Where each number comes from
  • Total revenues: “Total revenues were $4.1 billion, which was a 1.0% decrease year over year.”
  • Net earnings: “Net earnings were $825 million, or $1.63 per diluted share, compared with $599 million, or $1.11 per diluted share a year ago.”
  • Net earnings per diluted share: “Net earnings were $825 million, or $1.63 per diluted share, compared with $599 million, or $1.11 per diluted share a year ago.”
  • Adjusted earnings per diluted share: “Adjusted earnings per diluted share* decreased 1.7% to $1.75.”
  • Adjusted earnings: “Adjusted earnings* were $883 million, compared with $957 million a year ago, reflecting a decrease of 7.7%.”
  • Aflac Japan new annualized premium sales: “total new annualized premium sales (sales) decreased 5.6% to ¥19.6 billion, or $123 million, reflecting a high prior-year sales baseline for Miraito cancer insurance”
  • Aflac U.S. sales: “Aflac U.S. sales increased 2.6% in the quarter to $349 million, primarily benefiting from sales of group voluntary benefits and network dental and vision products.”
  • Aflac Japan premium persistency: “Persistency remained solid and in line with our expectations at 92.7%.”
  • Aflac U.S. persistency: “Premium persistency remained solid at 79.4%, up 20 basis points year over year.”

Copied from the press release ↗ and other documents in the SEC filing ↗. A figure is published only if its sentence is in those documents.

From the filingQ2 2026vs year agovs last quarter
Revenue$4.1B−1.0%−5.3%
Net income$825.0M+37.7%−19.0%
Diluted EPS$1.63+46.8%−17.7%

Calculated by code from XBRL, not by the model.

Outlook

MetricPeriodOutlook
Aflac Japan benefit ratio, high end of rangefull year 202660% to 63%
Aflac Japan expense ratio202620% - 23%
Aflac Japan pretax profit margin202633% - 36%
Aflac U.S. benefit ratio202648% - 52%
Aflac U.S. expense ratio202636% - 39%
Aflac U.S. pretax profit margin202617% - 20%
Aflac U.S. net earned premium growth2026just below our guidance range of 3% to 6%
Aflac U.S. net earned premium CAGR2025-20273% to 6%

Key takeaways

  1. Japan's new products offset a tough Miraito comparison

    Japan sales fell 5.6% to ¥19.6 billion because Miraito cancer insurance launched in March 2025. Strong growth in the refreshed Tsumitasu and Anshin Palette partly offset that, and first-half sales rose 7.0%.

  2. U.S. sales driven by group and network dental

    Aflac U.S. sales increased 2.6% to $349 million, mainly from group voluntary benefits and network dental and vision products. This shows the U.S. business moving toward employer-sponsored bundles.

  3. Japan reinsurance target raised to 30% of FSA reserves

    Aflac Japan moved from an internal target of up to 10% of U.S. GAAP assets to up to 30% of FSA reserves. Management says this reduces risk, improves balance sheet efficiency and should lift ROE.

  4. New products create elevated lapse and reissue activity

    Japan persistency was 92.7%, with somewhat elevated lapse and reissue activity on recently launched products as coverage options expanded. Lapses on the first sector savings block stayed low despite higher yen interest rates.

  5. U.S. premium growth guided just below range

    Management now expects 2026 U.S. net earned premium growth just below its 3% to 6% range, versus the low end before. It still expects the 2025-2027 compound growth rate to land within that range.

Charts

Revenue$4.1B−1.0% y/yQ2 2026
Q4 2024: $5.4B (worked out from the annual figure)Q4 ’24$5.4BQ1 2025: $3.4BQ1 ’25$3.4BQ2 2025: $4.2BQ2 ’25$4.2BQ3 2025: $4.7BQ3 ’25$4.7BQ4 2025: $4.9B (worked out from the annual figure)Q4 ’25$4.9BQ1 2026: $4.3BQ1 ’26$4.3BQ2 2026: $4.1BQ2 ’26$4.1BQ3 2026: $3.3BQ3 ’26$3.3B

Fourth quarter worked out from the annual figure.

Data
Q4 2024$5.4B *
Q1 2025$3.4B
Q2 2025$4.2B
Q3 2025$4.7B
Q4 2025$4.9B *
Q1 2026$4.3B
Q2 2026$4.1B
Q3 2026$3.3B
Diluted EPS (GAAP)$1.63+46.8% y/yQ2 2026
Q1 2025: $0.05Q1 ’25$0.05Q2 2025: $1.11Q2 ’25$1.11Q3 2025: $3.08Q3 ’25$3.08Q1 2026: $1.98Q1 ’26$1.98Q2 2026: $1.63Q2 ’26$1.63Q3 2026: $0.61Q3 ’26$0.61
Data
Q1 2025$0.05
Q2 2025$1.11
Q3 2025$3.08
Q1 2026$1.98
Q2 2026$1.63
Q3 2026$0.61

Fourth-quarter EPS appears once the press release is read; filings report it only for the full year.

Questions

Which products drove Aflac Japan's sales this quarter?

Refreshed Tsumitasu savings-type life insurance and Anshin Palette, a medical insurance product launched in December 2025, grew strongly. Miraito cancer insurance, launched in March 2025, faced a high prior-year baseline.

What is driving Aflac U.S. sales growth?

U.S. sales rose 2.6% to $349 million, mainly from group voluntary benefits and network dental and vision products. Management plans a stronger second-half push to get brokers to adopt network dental.

How is Aflac changing its reinsurance strategy in Japan?

Aflac Japan raised its reinsurance target to up to 30% of FSA reserves, replacing an internal target of up to 10% of U.S. GAAP assets. Management says it should reduce risk, improve balance sheet efficiency and raise ROE.

Is customer retention a concern in Japan?

Persistency was 92.7%, in line with expectations, with somewhat elevated lapse and reissue activity on newly launched products. Lapses on the first sector savings block remained low despite higher yen interest rates.

How did Aflac change its U.S. premium outlook?

It now expects 2026 net earned premium growth just below the 3% to 6% guidance range, versus the low end of the range previously. It still expects the 2025-2027 compound growth rate within the range.

Documents

SEC filing